Biotechnology Innovation Services
Call Us At 508-404-1120
Eugene L. (Gene) Brown is an innovative and collaborative scientist with 20-plus years of technical and leadership experience in the biotechnology and pharmaceutical industries. He is an expert in developing applications for new platform technologies related to identifying mechanism of disease studies, the discovery, and validation of drug targets and biomarkers, compound selection, and animal model validation. Gene is the Managing Member of Quicksilver Consultants, LLC, which provides professional services in platform technologies and life sciences tools.
At Wyeth Pharmaceuticals, Gene integrated genomic and proteomic technologies into numerous disease-focused therapeutic programs and was responsible for the oversight and critical review of Discovery Research microarray-based gene expression studies. A recent paper in Cancer Research illustrates his leadership in advocating the use of gene set enrichment analysis for animal model validation.
In support of Wyeth’s Parkinson’s disease program, Gene and a postdoctoral fellow (supported in part by the Michael J Fox Foundation for Parkinson’s Research) formulated a mass spectrometry-phosphoproteomics approach for the study of a mechanism of disease for leucine-rich repeat kinase 2 and its role in Parkinson’s disease. Using a combinatorial peptide library method they have identified a phosphorylation motif for the kinase and used it for the generation of an anti-motif antibody, which is in current use for a variety of disease characterization studies.
At Genetics Institute, Inc., Gene led a collaboration with Affymetrix, Inc., which demonstrated the performance of the GeneChip® platform for quantitative global mRNA analysis. Subsequently, he worked with bioinformatics colleagues to create an infrastructure for managing and converting gene expression data into biological information. Gene’s earliest contribution to Genetics Institute was the creation of a state-of-the-art DNA synthesis service group at a time when DNA synthesizers were not commercially available.